Lymphocytic Leukemia Clinical Trials

21 clinical trials for Lymphocytic Leukemia across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD — RECRUITING · PHASE2
• A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. — RECRUITING · PHASE1
• A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) — RECRUITING · PHASE3
• A MASTER PROTOCOL TO EVALUATE THE LONG-TERM SAFETY OF PIRTOBRUTINIB — NOT_YET_RECRUITING
• Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy — COMPLETED · PHASE1
• A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF SONROTOCLAX (BGB-11417) PLUS ZANUBRUTINIB (BGB-3111) COMPARED WITH VENETOCLAX PLUS ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA — NOT_YET_RECRUITING · PHASE3
• A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL — TERMINATED · PHASE1
• A GLOBAL MULTICENTER, OPEN LABEL, RANDOMIZED, PHASE 3 REGISTRATIONAL STUDY OF LISAFTOCLAX (APG-2575) IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA — NOT_YET_RECRUITING · PHASE3
• A GLOBAL PHASE 3, RANDOMIZED, OPEN-LABEL, MULTI-CENTER TRIAL DESIGNED TO COMPARE EFFIACY AND SAFETY OF LISOCABTAGENE MARALEUCEL VS INVESTIGATOR¿S CHOICE OPTIONS (IDEALISIB+RITUXIMAB OR BENDAMUSTINE +RITUXIMAB) IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WHOSE DISEASE HAS FAILED TREATMENT WITH BOTH BTKI AND BCL2I TARGETED THERAPIES (A DOUBLE CLASS EXPOSED POPULATION) — NOT_YET_RECRUITING · PHASE3
• Symbenda Post-Marketing Surveillance (PMS) — COMPLETED
• Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients — COMPLETED · PHASE2
• Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies — COMPLETED · PHASE1
• A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — COMPLETED · PHASE1
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies — COMPLETED · NA
• PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF MULTIPLE DOSE REGIMENS OF MT-3724 FOR THE TREATMENT OF PATIENTS WITH RELAPSED NON-HODGKIN¿S B-CELL LYMPHOMA AND B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA — COMPLETED
• Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies — COMPLETED
• Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — COMPLETED · PHASE1
• Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab — COMPLETED · PHASE2
• A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE IIIB, INTERNATIONAL STUDY EVALUATING THE SAFETY OF OBINUTUZUMAB ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED OR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA — COMPLETED · PHASE3
• A PHASE 2 OPEN-LABEL STUDY OF THE EFFICACY OF ABT-199 (GDC-0199) IN SUBJECTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA HARBORING THE 17P DELETION — COMPLETED · PHASE2
• This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL) — WITHDRAWN · PHASE3

Refine this search